Bloomage TangAn
华熙唐安生物科技（深圳）有限公司
A Bloomage-incubated synbio company in Guangming building a world-leading non-animal heparin/glycan platform via full-enzymatic synthesis — strong glycan/biomaterials pedigree, but not an open pilot-fermentation CDMO.
- Location
- Guangming District · Shenzhen
- Visit window
- From the Nanshan base · Jul 13–31
- Source status
- high confidenceprofiled
Next action
Keep the dossier ready and use the open questions if a visit window opens.
Why now: Visit window · From the Nanshan base · Jul 13–31
What they do
Founded 2023 and incubated by Bloomage Biotechnology, it focuses on biosynthesis of bioactive glycan molecules and innovative-drug development, aiming for a full-chain heparin-glycan platform via full-enzymatic in-vitro precision synthesis that replaces animal-tissue extraction. Product lines span glycan-engineering substrates, enzyme preparations, model glycan-chain libraries, cosmetics, Class-1 innovative drugs and medical devices.
Why it matters
Its Guangming full-enzymatic glycan biosynthesis and enzyme-mutant engineering are a credible biomanufacturing/enzyme-engineering reference for Pure Advance's discovery-plus-biomanufacturing core, and its HA/glycan heritage could supply non-anticoagulant glycans or polysaccharide excipients for the secondary Coolvex topical line. Fit is medium and indirect — the company is heparin/glycan-and-drug focused, not a general external fermentation CDMO.
Visit objective & route
Meet if introduced to benchmark their enzyme/glycan biomanufacturing platform and explore non-anticoagulant glycans or cosmetic excipients for the topical line.
Approach route
Appointment-only; fold into a Guangming synbio-cluster day near the national center. Keep the ask on non-anticoagulant glycans / cosmetic excipients.
Talking points
- Do you have non-anticoagulant glycans / HA derivatives suitable for topical skin-barrier or sensitive-area use?
- Can you supply ingredients or co-develop (rather than drug-development only), and could the Bloomage parent cosmetic/HA team join?
- How do you handle bleeding-risk / regulatory positioning of any heparin-adjacent molecule for a sensitive-area product?
- Bring the Pure Advance one-pager (AI-accelerated microbial biocontrols) and an NDA template.
Open questions
- Are there non-anticoagulant glycans / HA derivatives suitable for topical skin-barrier / sensitive-area use?
- Can they supply ingredients or co-develop (vs drug-development only), and can the Bloomage parent cosmetic/HA team join?
- Do they offer any external pilot-fermentation / enzymatic-synthesis service (likely not — confirm)?
- Regulatory positioning for any heparin-adjacent molecule given bleeding-risk concerns for sensitive-area application.
Risks & unknowns
- Heparin/glycan-and-drug focused, not a general external fermentation CDMO — don't assume manufacturing-for-hire access.
- Anticoagulant-heparin-related molecules carry bleeding-risk concerns inappropriate for a sensitive-area product; keep scope to non-anticoagulant glycans.
- No standalone public financials captured; verify collaboration access and commercial terms before relying on it.
Private-pack boundary